Alpharma (ALO) Resubmits New Drug Application for EMBEDA(TM) Capsules
More News related to ALO
- King Pharmaceuticals (KG) Responds to Alpharma (ALO)
- King Pharmaceuticals Responds to Alpharma Inc.
- Alpharma Board of Directors Unanimously Rejects King Pharmaceuticals' Unsolicited Tender Offer as "Financially Inadequate"
- Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
- Alpharma Licenses Durect's Novel Bupivacaine Patch
Alpharma Inc. (NYSE: ALO) today announced that it has resubmitted its New Drug Application for EMBEDA(TM) Capsules to the U.S. FDA. Alpharma is fully committed to collaborating with the FDA to complete a timely review of the EMBEDA(TM) Capsules NDA, and continues to anticipate a first quarter 2009 launch following approval.
Alpharma, Inc. develops, manufactures, and markets pharmaceutical products for humans and animals worldwide.
Related Categories
FDAStocks Mentioned
-2.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
